CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...